Visceral fat is different from regular fat because it actively harms metabolism, and tesamorelin reduces it in a way that improves long-term metabolic health by affecting fat quality, muscle, and mitochondria.
Scientific Claim
Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.
Original Statement
“So, here's where we're going today with this. We're going to talk about why visceral fat is a completely different problem than regular fat. And you might know this from videos I've done on this channel. Then, we're going to break down the human research showing how tessarellin reduces visceral fat and liver fat with clear cause and effect. And then, after that, we're going to get into something that almost no one talks about. We're going to talk about fat quality and muscle fat and why improving these changes your metabolism and how it behaves long term. And then we're going to connect this all to mitochondrial function and where this stops being about weight loss and starts being about more metabolic resilience.”
Context Details
Domain
pharmacology
Population
human
Subject
tesamorelin
Action
reduces
Target
visceral fat and improves fat quality, muscle composition, and mitochondrial efficiency
Intervention Details
Evidence from Studies
Supporting (5)
Unknown Title
The study shows that a drug called tesamorelin shrinks dangerous belly fat in HIV patients, which is good, but it didn’t prove the drug makes the body better at using insulin or improves muscle or energy factories in cells.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
In a clinical trial, tesamorelin was given to HIV patients with excess belly fat, and it was found to reduce both visceral and liver fat.
Tesamorelin improves fat quality independent of changes in fat quantity
Tesamorelin doesn’t just shrink belly fat—it makes the fat cells healthier and more efficient, which is good for your metabolism, even if the amount of fat doesn’t change much.
1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
This study found that tesamorelin, a growth hormone-releasing hormone analogue, can reduce visceral fat and liver fat in people with HIV who are taking certain types of antiretroviral therapy.
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
This study found that a drug called tesamorelin helped improve how well muscle cells use energy after exercise, which means the body’s power plants (mitochondria) got better at working — a sign of improved metabolic health.
Contradicting (2)
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)
A study comparing two diabetes medications found that both can help reduce visceral fat, but it doesn't specifically support the claim about tesamorelin.
Researchers found that certain factors can predict how much visceral fat will decrease after weight loss surgery, but it doesn't directly relate to tesamorelin's effects.